{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:20:33Z","timestamp":1783938033037,"version":"3.55.0"},"reference-count":34,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2024,9,30]]},"DOI":"10.1536\/ihj.24-069","type":"journal-article","created":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T22:14:14Z","timestamp":1727648054000},"page":"913-928","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Dapagliflozin in Combination with Hydrochlorothiazide on Cardiac Remodeling in Rats with Heart Failure After Myocardial Infarction"],"prefix":"10.1536","volume":"65","author":[{"given":"Jinghong","family":"Luo","sequence":"first","affiliation":[{"name":"State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University"},{"name":"Centre for Scientific Research, Department of Geriatrics, Huizhou Central People&apos;s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Huizhou Central People&apos;s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zeng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gonz\u00e1lez A, Schelbert EB, Diez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol 2018; 71: 1696-706.","DOI":"10.1016\/j.jacc.2018.02.021"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dorn GW 2nd, Molkentin JD. Manipulating cardiac contractility in heart failure: data from mice and men. Circulation 2004; 109: 150-8.","DOI":"10.1161\/01.CIR.0000111581.15521.F5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Zinman B, Wanner C, Lachin JM, <i>et al<\/i>. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.","DOI":"10.1056\/NEJMoa1504720"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Packer M, Anker SD, Butler J, <i>et al<\/i>. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413-24.","DOI":"10.1056\/NEJMoa2022190"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wiviott SD, Raz I, Bonaca MP, <i>et al<\/i>. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-57.","DOI":"10.1056\/NEJMoa1812389"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. McMurray JJV, Solomon SD, Inzucchi SE, <i>et al<\/i>. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Neal B, Perkovic V, Matthews DR, <i>et al<\/i>. Rationale, design and baseline characteristics of the CANagliflozin cardio Vascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab 2017; 19: 387-93.","DOI":"10.1111\/dom.12829"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dyck JRB, Sossalla S, Hamdani N, <i>et al<\/i>. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol 2022; 167: 17-31.","DOI":"10.1016\/j.yjmcc.2022.03.005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zelniker TA, Braunwald E. Mechanisms of cardio renal effects of sodium glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75: 422-34.","DOI":"10.1016\/j.jacc.2019.11.031"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hou YC, Zheng CM, Yen TH, Lu KC. Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int J Mol Sci 2020; 21: 7833.","DOI":"10.3390\/ijms21217833"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zhang Y, Li YM, Cheng GC. Effect of low-dose diuretics on the level of serum cystatin C and prognosis in patients with a symptomatic chronic heart failure. Exp Ther Med 2015; 10: 2345-50.","DOI":"10.3892\/etm.2015.2837"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Liu C, Lai YX, Guan TW, Shen Y, Pan Y, Wu D. Outcomes of diuretics in rheumatic heart disease with compensated chronic heart failure: a retrospective study. ESC Heart Fail 2020; 7: 3929-41.","DOI":"10.1002\/ehf2.12987"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Luo J, Gao X, Peng L, Sun H, Dai G. Effects of hydrochlorothiazide on cardiac remodeling in arat model of myocardial infarction-induced congestive heart failure. Eur J Pharmacol 2011; 667: 314-21.","DOI":"10.1016\/j.ejphar.2011.06.012"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Luo J, Chen X, Luo C, <i>et al<\/i>. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. Cardiovas Ther 2017; 35: e12246.","DOI":"10.1111\/1755-5922.12246"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chang PC, Lin SF, Chu Y, <i>et al<\/i>. LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model. Cardiovasc Ther 2019; 2019: 6032631.","DOI":"10.1155\/2019\/6032631"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Jin H, Fujita T, Jin M, <i>et al<\/i>. Cardiac over expression of Epac 1 in transgenic mice rescues lipopolysaccharide-induced cardiac dysfunction and inhibits Jak-STAT pathway. J Mol Cell Cardiol 2017; 108: 170-80.","DOI":"10.1016\/j.yjmcc.2017.05.014"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Okumura S, Fujita T, Cai W, <i>et al<\/i>. Epac1-dependent phospholamban phosphorylation mediates the cardiac response tostresses. J Clin Invest 2014; 124: 2785-801.","DOI":"10.1172\/JCI64784"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Liu Z, Mar KB, Hanners NW, <i>et al<\/i>. ANIK-SIX signaling axis controls inflammation by targeted silencing of non-canonical NF-\u03baB. Nature 2019; 568: 249-53.","DOI":"10.1038\/s41586-019-1041-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Asano S, Nemoto T, Kitayama T, <i>et al<\/i>. Phospholipase C-related catalytically in active protein (PRIP) controls KIF5B-mediated insulin secretion. Biol Open 2004; 3: 463-74.","DOI":"10.1242\/bio.20147591"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chao Y, Ye P, Zhu LL, <i>et al<\/i>. Low shear stress induces endothelial reactive oxygen species via the AT1R\/eNOS\/NO pathway. J Cell Physiol 2018; 233: 1384-95.","DOI":"10.1002\/jcp.26016"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mcdonald M, Virani S, Chan M, <i>et al<\/i>. CCS\/CHFS Heart Failure Guidelines Update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 2021; 37: 531-46.","DOI":"10.1016\/j.cjca.2021.01.017"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Zhang Y, Li Y, Cheng G. Effect of low-dose diuretics on the level of serum cystatin C and prognosis in patients with a symptomatic chronic heart failure. Exp Ther Med 2015; 10: 2345-50.","DOI":"10.3892\/etm.2015.2837"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Liu C, Lai Y, Guan T, Shen Y, Pan Y, Wu D. Outcomes of diuretics in rheumatic heart disease with compensated chronic heart failure: a retrospective study. ESC Heart Failure 2020; 7: 3929-41.","DOI":"10.1002\/ehf2.12987"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ito H, Ishii K, Kihara H, <i>et al<\/i>. Adding thiazide to are nin-angiotens in blocker improves left ventricular relaxation and improves heart failure in patients with hypertension. Hypertens Res 2012; 35: 93-9.","DOI":"10.1038\/hr.2011.169"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Arias SC, Souza RA, Malheiros DM, Fanelli C, Fujihara CK, Zatz R. An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney. Am J Physiol Renal Physiol 2016; 310: F135-43.","DOI":"10.1152\/ajprenal.00388.2015"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ceron CS, Castro MM, Rizzi E, <i>et al<\/i>. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010; 160: 77-87.","DOI":"10.1111\/j.1476-5381.2010.00678.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Orlowski J, Grinstein S. Na<sup>+<\/sup>\/H<sup>+<\/sup> exchangers. Compr Physiol 2011; 1: 2083-100.","DOI":"10.1002\/cphy.c110020"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Padan E, Landau M. Sodium-proton (Na(+)\/H(+)) antiporters: properties and roles in health and disease. Met Ions Life Sci 2016; 16: 391-458.","DOI":"10.1007\/978-3-319-21756-7_12"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Odunewu-Aderibigbe A, Fliegel L. The Na(+)\/H(+) exchanger and pH regulation in the heart. IUBMB Life 2014; 66: 679-85.","DOI":"10.1002\/iub.1323"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S. Activation of Na<sup>+<\/sup>\/H<sup>+<\/sup> exchanger1 is sufficient to generate Ca<sup>2+<\/sup> signals that induce cardiac hypertrophy and heart failure. Circ Res 2008; 103: 891-9.","DOI":"10.1161\/CIRCRESAHA.108.175141"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kili\u0107 A, Huang CX, Rajapurohitam V, Madwed JB, Karmazyn M. Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation. J Pharmacol Exp Ther 2014; 351: 492-9.","DOI":"10.1124\/jpet.114.217091"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Baartscheer A, Schumacher CA, W\u00fcst RC, <i>et al<\/i>. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia 2017; 60: 568-73.","DOI":"10.1007\/s00125-016-4134-x"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Uthman L, Baartscheer A, Bleijlevens B, <i>et al<\/i>. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na<sup>+<\/sup>\/H<sup>+<\/sup> exchanger, lowering of cytosolic Na<sup>+<\/sup> and vasodilation. Diabetologia 2018; 61: 722-6.","DOI":"10.1007\/s00125-017-4509-7"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Uthman L, Li X, Baartscheer A, <i>et al<\/i>. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na+]c\/ROS-pathway in human endothelial cells. Biomed Pharmacother 2022; 146: 112515.","DOI":"10.1016\/j.biopha.2021.112515"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/5\/65_24-069\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T04:11:32Z","timestamp":1728101492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/5\/65_24-069\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.24-069","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"article-number":"24-069"}}